Sofwave Medical Reports Second Quarter and First Half 2023 Financial results with continued growth in revenue and narrow in operating loss. Second quarter revenue of $12.4M, +53% year-over-year growth. First-half revenue of $22.8M, +67% year-over-year growth. Operating loss significantly narrows in both the second quarter and first half periods and moves closer to reaching operating break-even.
Sofwave Medical reports first quarter fiscal 2023 financial results and recent business highlights. First quarter revenue of $10.4M, +86% Year-Over-Year Growth with over 125,000 treatments performed since initial approval; Global market conditions remain favorable, and demand continues to grow in the noninvasive skin treatments sector, with recurring revenues up 74%, to $2.2M. To learn more, please watch the video.
Sofwave™ Medical LTD reports financial results for the period of January – June 2022 (H1/2022) with accelerated growth in revenues and gross margin. The first half of 2022 revenues reached $13.7 million, an increase of 34% YoY growth, and $2.9 million in recurring revenue from our pulse sales, representing 202% YoY growth. This increase was primarily attributed to the continued marketing and sales investments in the Company’s primary markets and increased demand for the Company’s solutions. To learn more, please watch the video.
This exclusive webinar brings together our Sofwave™ management and investors with Dr. David Goldberg to discuss our unique technology, FDA indications, practice ROI and compares our proprietary SUPERB™ technology with existing treatments in the market.
Please note that the following webinar is in both Hebrew and English.
Sofwave™ Medical LTD reports financial results for the full year 2021 with accelerated growth in revenues and gross margin. 2021 revenues reached $21.8 million, an increase of 408% compared to 2020. This increase was primarily attributed to the continued marketing and sales investments in the Company’s primary markets and increased demand for the Company’s solutions. To learn more please watch the video.
This presentation contains forward-looking statements, reflecting Sofwave’s current expectations regarding future events. These statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion and the commercialization of the products herein.
Stock Exchange Updates
Sep 26, 2023
Symbol : SOFW
SOFW : TASE
Last Update: 2023-09-26 07:43:27
Sofwave Company Profile
Commitment & Passion
Driven by experience and passion, Sofwave Medical is a fast-growing medical aesthetic technology innovator committed to developing cutting-edge technologies for the global aesthetic market.
Sofwave Medical’s breakthrough technology brings a new standard of care to aesthetic treatments, providing physicians with smart yet simple, effective and safe aesthetic treatments for their patients.
Heritage of Innovation
From key founders of the aesthetic industry, Sofwave Medical brings a novel approach to non-invasive skin treatments using proprietary Synchronous Ultrasound Parallel Beam Technology SUPERB™.
Chairman & Co-Founder
COO & Site Manager
Chief Medical Officer
Chief Digital Officer
Co-Founder and CTO